Analysts Are Bullish on These Healthcare Stocks: Clene (CLNN), I-MAB (IMAB)
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $31
Buy Rating Justified by Regulatory Progress and Positive ALS Treatment Data for Clene's CNM-Au8
Clene Analyst Ratings
EF Hutton Initiates Clene at Buy With $23 Price Target
EF Hutton Initiates Clene(CLNN.US) With Buy Rating, Announces Target Price $23
Clene Analyst Ratings
Buy Rating Justified for Clene Amidst Promising ALS Trial Results and Potential Accelerated FDA Approval
Clene Analyst Ratings
Canaccord Genuity Reiterates Buy on Clene, Maintains $94 Price Target
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price Target
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price Target
Clene Analyst Ratings
Clene Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price Target
Clene Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK), Biogen (BIIB) and Clene (CLNN)
HC Wainwright & Co. : Clene (CLNN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $7.00.
Clene Analyst Ratings